Cited by Integrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening

Inhibition of Cyp1a Protects Mice against Anthracycline Cardiomyopathy DOI

Jing Liu, Casie Curtin, Rahul K. Lall

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 11, 2024

ABSTRACT Background Anthracyclines such as doxorubicin (Dox) are highly effective anti-tumor agents, but their use is limited by dose-dependent cardiomyopathy and heart failure. Our laboratory previously reported that induction of cytochrome P450 family 1 (Cyp1) enzymes contributes to acute Dox cardiotoxicity in zebrafish mice, potent Cyp1 inhibitors prevent cardiotoxicity. However, the role chronic cardiomyopathy, well mechanisms underlying cardioprotection associated with inhibition, have not been fully elucidated. Methods The pathway was evaluated using a small molecule inhibitor wild-type (WT) or Cyp1-null mice ( Cyp1a1/1a2 -/- , Cyp1b1 Cyp1a1/1a2/1b1 ). Low-dose administered serial intraperitoneal intravenous injections, respectively. Expression isoforms measured RT-qPCR, myocardial tissue isolated from left ventricle for RNA sequencing. Cardiac function transthoracic echocardiography. Results In WT treatment decrease Cyp1a2 increase expression liver. Co-treatment novel YW-130 protected against cardiac dysfunction compared alone. were mice. Male, female, had increased following sequencing showed upregulation Fundc1 downregulation Ccl21c treated Dox, implicating changes mitophagy chemokine-mediated inflammation possible Cyp1a-mediated cardioprotection. Conclusions Taken together, this study highlights potential therapeutic value Cyp1a inhibition mitigating anthracycline cardiomyopathy.

Language: Английский

Citations

Engineered Heart Emulation: Combining Molten Electrostatic Direct Writing and Microfluidics for Constructing a Cardiomyocytes-on-A-Chip for Drug Screening DOI

Yuhong Wang,

Tingting Liu,

Yanping Guo

et al.

Published: Jan. 1, 2024

Language: Английский

Citations

Capturing Hydrophilic Chemotherapeutics Agents Into siRNA‐Encapsulated Vesicle‐Like Nanoparticles for Convenient ICB‐Chemo Combination Therapy DOI

Yan Li, Bingqin Li, Chaoran Chen

et al.

Small, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 5, 2024

Abstract Clinical evidence has demonstrated that combining immune checkpoint blockade (ICB) therapy with chemotherapy significantly improves response rates to ICB and therapeutic efficacy in various tumor types. However, a convenient method for achieving synergistic precise co‐delivery of both agents is still highly desirable. In this study, strategy co‐delivering small interfering RNA (siRNA) encapsulated vesicle‐like nanoparticles (VNP siRNA ) chemotherapeutic drugs aimed develop. It discovered the hydrophilic drug mitoxantrone hydrochloride (MTO·2HCl) can be captured into VNP . The resulting Cp MTO simultaneously block checkpoints via silencing induce effects on cells. mechanism MTO·2HCl elucidates, captures, demonstrates superior effect through chemo‐immunotherapy. This also extended deliver other anticancer drugs, such as doxorubicin (DOX·HCl), combination therapy. study provides facile enhancing combined offering promising approach cancer treatment.

Language: Английский

Citations

Integrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening DOI

Yuhong Wang,

Tingting Liu,

Yanping Guo

et al.

Bioactive Materials, Journal Year: 2024, Volume and Issue: 45, P. 551 - 566

Published: Dec. 11, 2024

Language: Английский

Citations